Abstract
Objective To compare the burden of communicable and non-communicable diseases (NCDs) in the USA and globally, particularly among 15-45 years old.
Methods The imported data from the WHO Mortality Database portal was analyzed by SPSS.
Results The study shows the percentage of death from NCDs out of total death in the USA in 2010 and 2019 were 86.7% and 86.8% which are higher than global rates of 78.1% and 80.2%. Despite a similar death percentage out of total death, the death rate due to NCDs increased from 601.04/100,000 (2010) to 687.99/100,000 (2019) and 790.29/100,000 (2020) globally; and from 693.60/100,000 (2010) to 753.35/100000 (2019) and 795.78/100000 (2020) in the USA. On the other hand, the death rate from communicable diseases were 56.57/100000, 55.52/100000, and 129.47/100000 globally; and 44.63/100000, 43.20/100000, and 151.99/100000 in the USA in the respective years. Young adults of 15-45 years show a higher NCD death rate in the USA with an increasing trend.
Conclusion The USA has a higher NCDs dependent mortality rate relative to the global mortality rate, particularly among the 15-45 years age group. During the COVID-19 pandemic, the relative raising in the communicable disease death rate indicates an interplay between communicable and NCDs.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
